Abstract No. 518 Comprehensive analysis of treatment response and survival profiles in hepatocellular carcinoma patients: drug-eluting beads transarterial chemoembolization with CalliSpheres microspheres versus conventional transarterial chemoembolization

Abstract

The aim of this study was to compare the treatment response and survival profiles between drug-eluting beads transarterial chemoembolization (DEB-TACE) with CalliSpheres® microspheres (CSM) and conventional transarterial chemoembolization (cTACE) in hepatocellular carcinoma (HCC) patients. Three hundred and thirty-five HCC patients receiving DEB-TACE with CSM or cTACE were consecutively enrolled in this multi-center, retrospective cohort study, whom were divided into DEB-TACE group and cTACE group accordingly. Treatment response were assessed by enhanced CT or MRI according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) at month 1 (M1), M3, and M6 after treatment. Progression free survival (PFS) and overall survival (OS) were assessed. Complete response (CR) at M3 (P=0.020) and objective response rate (ORR) at M1 (P<0.001), M3 (P<0.001) and M6 (P=0.018) were elevated in DEB-TACE group compared with cTACE group. In addition, progression free survival (PFS) (P=0.503) and overall survival (OS) (P=0.203) did not vary between DEB-TACE and cTACE group. DEB-TACE independently correlated with elevated ORR at M1 (P=0.002) and more prolonged OS (P=0.023). In addition, ALP abnormal independently associated with lower ORR at M3, history of drink and largest nodule size ≥7 cm were independent predictive factors for decreased ORR at M6. Largest nodule size ≥7 cm and ALB abnormal were independent predicting factors for shorter PFS, Child-Pugh stage B/C, ALB abnormal, ALP abnormal and AFP abnormal were independently associated with unfavorable OS. DEB-TACE with CSM presents with more favorable treatment response and survival profile compared with cTACE in HCC patients.TableComparison of Treatment Response Between the DEB-TACE and cTACE GroupsM1M1M1M2M2M2M3M3M3DEB-TACE GroupcTACE GroupP ValueDEB-TACE GroupcTACE GroupP ValueDEB-TACE GroupcTACE GroupP ValueNumber of assessed patients10712482555445CR (n/%)13(12.1)10(8.1)0.30116(19.5)3(5.5)0.0209(16.7)3(6.7)0.129PR (n/%)64(59.8)48(38.7)0.00147(57.3)22(40.0)0.04729(53.7)18(40.0)0.174SD (n/%)19(17.8)50(40.3)<0.0015(6.1)21(38.1)<0.00110(18.5)15(33.3)0.091PD (n/%)11(10.3)16(12.9)0.53614(17.1)9(16.4)0.9136(11.1)9(20.0)0.219ORR (n/%)77(71.9)58(46.8)<0.00163(76.8)25(45.5)<0.00138(70.4)21(46.7)0.018DCR (n/%)96(89.7)108(87.1)0.53668(82.9)46(83.6)0.91348(88.9)36(80.0)0.219 Open table in a new tab